Scholars Central

Review articlePublished 2014

Advantages and Disadvantages of Targeting the C-erbB Family of Receptors in Cancer Treatment: A Review

Authors: Panagiotis Papanastasopoulos

Biology and Medicine

Volume 6 · Issue 2

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

C-erbB (EGFR) signaling is well known to promote cancer invasiveness and metastasis. Several pharmacologic approaches have been used aiming to inhibit its activity, ie monoclonal antibodies, antibody-like molecules (peptidomimetics) and receptor tyrosine kinase inhibitors. Several C-erbB signaling ‘inhibitors’, such as Trastuzumab, Cetuximab, gefitinib, erlotinib and lapatinib are now widely used in clinical practice, having revolutionized the management of certain malignancies, such as HER-2 positive breast cancer. In this review, we present an overview of the mechanism of action, pharmacokinetic properties, mechanism of resistance as well as the relative cost of administration for each group of EGFR inhibitors separately.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Biology and Medicine.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalBiology and Medicine
  • SubjectNursing & Healthcare
  • BylineArticles whose byline prints “Panagiotis Papanastasopoulos”